Results 61 to 70 of about 93,278 (263)
Background: To investigate differences in disease severity and outcomes among COVID-19 patients with a history of hypertension using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other antihypertensive drugs.
Seyedpouzhia Shojaei +7 more
doaj +1 more source
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić +7 more
wiley +1 more source
Medication Literacy in a Cohort of Chinese Patients Discharged With Essential Hypertension
Background: In recent years, research on medication literacy has increased in many countries. Medication literacy in patients with essential hypertension affects the management and prognosis of hypertension.Method: This is a cross-sectional study of 147 ...
Zhuqing Zhong +8 more
doaj +1 more source
Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra +8 more
wiley +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Milestones in Antihypertensive Drug Treatment
Hypertension provoked since the beginning of the 19th century a medical debate between physicians. The early antihypertensive agents were poorly tolerated. Progress towards more effective drugs, appeared after the 2nd World War. Thiocyanates, dehydrogenated alkaloids of ergot, barbiturates, bismuth and bromides, were soon replaced by phenoxbenzamine ...
Tsoucalas, G. +5 more
openaire +3 more sources
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga +20 more
wiley +1 more source
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon +7 more
wiley +1 more source
ABSTRACT Background The European Society of Cardiology (ESC) guidelines for peripheral artery disease recommend antithrombotic strategies based on high ischemic risk (HIR) and high bleeding risk (HBR) criteria. However, their prognostic value in patients with lower extremity artery disease (LEAD) undergoing endovascular therapy (EVT) remains unclear ...
Hirokazu Shimono +8 more
wiley +1 more source
Drug interactions are one of the Drug Related Problems (DRPs) that may affect patient treatment outcomes. Hypertension occurs in approximately 10% to 81.5% of hemodialysis patients.
Siti Rahmiati, Woro Supadmi
doaj +1 more source

